Skip to main content

Table 4 Summary of changes in all survey responses by treatment and time

From: Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial

  

Placebo

Ambrisentan

Measure

Change period

Change (95% CI)

Change P -value

Overall P -value

Change (95% CI)

Change P -value

Overall P -value

S-HAQ

1 W - Base

−0.13 (−0.33,0.08)

0.22

0.14

−0.12 (−0.23,-0.00)

0.048

0.005

 

12 W - Base

−0.20 (−0.40,0.00)

0.051

 

−0.20 (−0.32,-0.08)

0.001

 
 

12 W - 1 W

−0.08 (−0.28,0.13)

0.45

 

−0.09 (−0.21,0.03)

0.15

 

RCS

1 W - Base

−0.20 (−1.74,1.34)

0.79

0.95

0.20 (−0.69,1.09)

0.65

0.001

 

12 W - Base

−0.20 (−1.74,1.34)

0.79

 

−1.46 (−2.37,-0.55)

0.002

 
 

12 W - 1 W

−0.00 (−1.54,1.54)

0.99

 

−1.66 (−2.57,-0.75)

<0.001

 

P-VAS

1 W - Base

0.20 (−0.95,1.35)

0.73

0.19

−0.47 (−1.13,0.20)

0.16

0.14

 

12 W - Base

−0.80 (−1.95,0.35)

0.17

 

−0.66 (−1.35,0.02)

0.056

 
 

12 W - 1 W

−1.00 (−2.15,0.15)

0.087

 

−0.20 (−0.88,0.49)

0.56

 
  1. P-values are from repeated measure analysis of variance models. Base = baseline; W = week; CI, confidence interval; P-VAS, Visual Analog Scale for Pain; RCS, Raynaud’s Condition Score; S-HAQ, Scleroderma Health Assessment Questionnaire.